The authors have demonstrated an important new role of protein O-GlcNAcylation in regulating pancreatic cancer TRAIL resistance; and uncovered the contribution of O-GlcNAcylation to TRAIL activation-induced oligomerization of death receptor 5 and apoptosis signaling. These findings support the potential use of O-GlcNAcylation inhibitors to enhance efficacy of TRAIL therapy.
- Shan-zhong Yang
- Fei Xu
- Yabing Chen